Regorafenib/Nivolumab Exhibits Nonsuperior Survival in Gastric Cancer

Regorafenib (Stivarga) plus nivolumab (Opdivo) displayed noninferior survival and a numerically higher response rate and disease control rate (DCR) compared with chemotherapy for patients with previously treated, refractory, advanced gastric or…